Onivyde for the therapy of multiple solid tumors

References

• XiaoXGXiaSZouMThe relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancerOnco Targets Ther201583575358326664141
   PubMed Web of Science ®Google Scholar
• LiuYLuanLWangXA randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutationOnco Targets Ther201581061106825999741
   PubMed Web of Science ®Google Scholar
• SuenagaMMizunumaNMatsusakaSPhase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN studyDrug Des Devel Ther2015930993108
   Web of Science ®Google Scholar
• RyugeSJiangSXWadaMLong-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecanDrug Des Devel Ther20093213217
   Web of Science ®Google Scholar
• Garcia-CarboneroRSupkoJGCurrent perspectives on the clinical experience, pharmacology, and continued development of the camptothecinsClin Cancer Res20028364166111895891
   PubMed Web of Science ®Google Scholar
• MathijssenRHvan AlphenRJVerweijJClinical pharmacokinetics and metabolism of irinotecan (CPT-11)Clin Cancer Res2001782182219411489791
   PubMed Web of Science ®Google Scholar
• DrummondDCNobleCOGuoZHongKParkJWKirpotinDBDevelopment of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategyCancer Res20066663271327716540680
   PubMed Web of Science ®Google Scholar
• KangMHWangJMakenaMRActivity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing’s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expressionClin Cancer Res20152151139115025733708
   PubMed Web of Science ®Google Scholar
• RivoryLPMetabolism of CPT-11. Impact on activityAnn N Y Acad Sci200092220521511193896
   PubMed Web of Science ®Google Scholar
• Etienne-GrimaldiMCBoyerJCThomasFUGT1A1 genotype and irinotecan therapy: general review and implementation in routine practiceFundam Clin Pharmacol201529321923725817555
   PubMed Web of Science ®Google Scholar
• AkimotoKKawaiAOhyaKKinetic-studies of the hydrolysis and lactonization of camptothecin and its derivatives, Cpt-11 and Sn-38, in aqueous-solutionChem Pharm Bull (Tokyo)19944221352138
   Web of Science ®Google Scholar
• TsaiCSParkJWChenLTNanovector-based therapies in advanced pancreatic cancerJ Gastrointest Oncol20112318519422811849
   PubMedGoogle Scholar
• ZhangHMultifunctional nanomedicine platforms for cancer therapyJ Nanosci Nanotechnol20121254012401822852341
   PubMed Web of Science ®Google Scholar
• ZhangHWangCChenBWangXDaunorubicin-TiO2 nanocomposites as a “smart” pH-responsive drug delivery systemInt J Nanomedicine2012723524222275838
   PubMed Web of Science ®Google Scholar
• ZhangHXiongJGuoLPatelaNGuangXIntegrated traditional Chinese and western medicine modulator for overcoming the multidrug resistance with carbon nanotubesRSC Adv201557128771296
   Web of Science ®Google Scholar
• ZhangHPatelaNXiongJDingSTargeting and noninvasive treatment of hepatocellular carcinoma in situ by ZnO nanorod-mediated concurrent chemoradiotherapyRSC Adv201558572085729
   Web of Science ®Google Scholar
• TahoverEPatilYPGabizonAAEmerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomesAnticancer Drugs201526324125825415656
   PubMed Web of Science ®Google Scholar
• RoyACParkSRCunninghamDA randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinomaAnn Oncol20132461567157323406728
   PubMed Web of Science ®Google Scholar
• ChibaudelBMaindrault-GoebelFAndréTPEPCOL: a randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer – a GERCOR StudyJ Clin Oncol201533Suppl 3 Abstr 751
   Web of Science ®Google Scholar
• KoAHTemperoMAShanYSA multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancerBr J Cancer2013109492092523880820
   PubMed Web of Science ®Google Scholar
• Von HoffDLiCPWang-GillamANapoli-1: randomized phase 3 study MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapyAnn Oncol201425Suppl 2ii105ii106
   Google Scholar
• ChangTCShiahHSYangCHPhase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patientsCancer Chemother Pharmacol201575357958625577133
   PubMed Web of Science ®Google Scholar
• KalraAVKimJKlinzSGPreclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversionCancer Res201474237003701325273092
   PubMed Web of Science ®Google Scholar
• ZhangHApatinib for molecular targeted therapy in tumorDrug Des Devel Ther2015960756081
   PubMed Web of Science ®Google Scholar
• WesolowskiRLeeCKimRIs there a role for second-line chemotherapy in advanced gastric cancer?Lancet Oncol200910990391219717092
   PubMed Web of Science ®Google Scholar
• LordickFGastrointestinal cancer: salvage chemotherapy in gastric cancer – more than a straw?Nat Rev Clin Oncol20129631231322547215
   PubMed Web of Science ®Google Scholar
• LiangRFZhengLLThe efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trialsDrug Des Devel Ther2015944714478
   Web of Science ®Google Scholar
• SuenagaMMizunumaNMatsusakaSA phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancerDrug Des Devel Ther2015916531662
   Web of Science ®Google Scholar
• WangCZhangHChenYShiFChenBGambogic acid-loaded magnetic Fe(3)O(4) nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1Int J Nanomedicine2012778178722393285
   PubMed Web of Science ®Google Scholar
• WangCZhangHChenBYinHWangWStudy of the enhanced anticancer efficacy of gambogic acid on Capan-1 pancreatic cancer cells when mediated via magnetic Fe3O4 nanoparticlesInt J Nanomedicine201161929193521931488
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200725151960196617452677
   PubMed Web of Science ®Google Scholar
• ConroyTDesseigneFYchouMFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
   PubMed Web of Science ®Google Scholar
• VaccaroVSperdutiIMilellaMFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011365876876921864184
   PubMed Web of Science ®Google Scholar
• Wang-GillamALiCPBodokyGPhase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapyJ Clin Oncol201634Suppl 4S Abstr 417
   Google Scholar